Global Markets Direct’s, 'Abscess - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Abscess, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Abscess. Abscess - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Abscess. - A review of the Abscess products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Abscess pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Abscess. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Abscess pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Abscess - Pipeline Review, H1 2013 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Abscess Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Abscess 7 Abscess Therapeutics under Development by Companies 9 Abscess Therapeutics under Investigation by Universities/Institutes 10 Late Stage Products 11 Comparative Analysis 11 Mid Clinical Stage Products 12 Comparative Analysis 12 Pre-Clinical Stage Products 13 Comparative Analysis 13 Abscess Therapeutics - Products under Development by Companies 14 Abscess Therapeutics - Products under Investigation by Universities/Institutes 15 Companies Involved in Abscess Therapeutics Development 16 Novartis AG 16 Toyama Chemical Co. Ltd 17 Trius Therapeutics, Inc. 18 Durata Therapeutics Inc. 19 Abscess - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 25 pasireotide - Drug Profile 25 Product Description 25 Mechanism of Action 25 RandD Progress 25 dalbavancin - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 tedizolid phosphate - Drug Profile 30 Product Description 30 Mechanism of Action 30 RandD Progress 30 piperacillin sodium - Drug Profile 32 Product Description 32 Mechanism of Action 32 RandD Progress 32 Drug For Staphylococcus aureus Infections - Drug Profile 33 Product Description 33 Mechanism of Action 33 RandD Progress 33 Abscess Therapeutics - Drug Profile Updates 34 Abscess Therapeutics - Dormant Products 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 47 Disclaimer 47
List of Tables
Number of Products Under Development for Abscess, H1 2013 7 Products under Development for Abscess - Comparative Analysis, H1 2013 8 Number of Products under Development by Companies, H1 2013 9 Number of Products under Investigation by Universities/Institutes, H1 2013 10 Comparative Analysis by Late Stage Development, H1 2013 11 Comparative Analysis by Mid Clinical Stage Development, H1 2013 12 Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13 Products under Development by Companies, H1 2013 14 Products under Investigation by Universities/Institutes, H1 2013 15 Novartis AG, H1 2013 16 Toyama Chemical Co. Ltd, H1 2013 17 Trius Therapeutics, Inc., H1 2013 18 Durata Therapeutics Inc., H1 2013 19 Assessment by Monotherapy Products, H1 2013 20 Assessment by Stage and Route of Administration, H1 2013 22 Assessment by Stage and Molecule Type, H1 2013 24 Abscess Therapeutics - Drug Profile Updates 34 Abscess Therapeutics - Dormant Products 45
List of Figures
Number of Products under Development for Abscess, H1 2013 7 Products under Development for Abscess - Comparative Analysis, H1 2013 8 Products under Development by Companies, H1 2013 9 Products under Investigation by Universities/Institutes, H1 2013 10 Late Stage Products, H1 2013 11 Mid Clinical Stage Products, H1 2013 12 Pre-Clinical Stage Products, H1 2013 13 Assessment by Monotherapy Products, H1 2013 20 Assessment by Route of Administration, H1 2013 21 Assessment by Stage and Route of Administration, H1 2013 22 Assessment by Molecule Type, H1 2013 23 Assessment by Stage and Molecule Type, H1 2013 24